Tibial bone versican content decreases with zoledronate treatment in adult mice.
In bone remodeling, the expression and turnover of the proteoglycans versican and aggrecan are poorly understood. We report changes in adult mouse bone contents of versican and aggrecan associated with both age and treatment with the drug zoledronate. The data may have implications for experimental animal models of osteoporosis and related conditions.


BACKGROUND
Versican and aggrecan are large, aggregating proteoglycans involved in skeletal development, but little is known about their roles in bone remodeling. The purpose of this study was to investigate versican and aggrecan contents in adult mouse bones, and changes in their contents in response to the bisphosphonate zoledronate (ZOL).


METHODS
Mice (9 weeks old) were treated with 125 μg/kg ZOL or vehicle for 3 or 15 weeks. Versican and aggrecan were isolated from tibial bones for Western blotting, automated integrated densitometry, and analysis (two-way ANOVA, α = 0.05).


RESULTS
In ZOL-treated mouse bones, compared to vehicle, 340 and 60 kDa versican content decreased significantly, and 100 and 60 kDa aggrecan content decreased significantly (drug effect). In 24-week-old mouse bones, compared to 12 weeks, statistically significant decreases were observed in 340, 80, 60, and 11 kDa versican, and in 100, 70, and 40 kDa aggrecan (age effect). There was a statistically significant ZOL-age interaction for 330 kDa aggrecan.


CONCLUSIONS
This is the first study to assess physiological versican and aggrecan adaptations in adult mammalian bone tissue, in the presence and absence of ZOL. We observed large decreases in some versican and aggrecan species from 12 to 24 weeks. We also observed decreases in several versican and aggrecan species in the presence of ZOL. This indicates that bone proteoglycan expression and turnover may be important in bone remodeling.
Northern Medical Program, University of Northern British Columbia, Prince George, BC, Canada.
S B
SB
Maurice
T
T
Bell
T
T
Daniels
C R
CR
Fetterly
D R
DR
Nelson
P J
PJ
Winwood
W T
WT
Bourque
R L
RL
Harris
D053674:Aggrecans / Q000378:metabolism; D000375:Aging / Q000378:metabolism; D000818:Animals; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D016723:Bone Remodeling / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology*; D005260:Female; D007093:Imidazoles / Q000494:pharmacology*; D008810:Mice, Inbred C57BL; D013977:Tibia / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D053675:Versicans / Q000378:metabolism*; D000077211:Zoledronic Acid
D053674:Aggrecans; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; C508323:Vcan protein, mouse; D053675:Versicans; D000077211:Zoledronic Acid